The past century brought incredible progress in health. With innovative diagnostics and medicines, healthcare professionals now have powerful tools to prevent, diagnose, treat and manage disease, helping people to live longer and healthier lives.
But our collective efforts must continue. While living longer is a triumph, it presents a challenge: to maintain sustainable health systems at a time of ageing populations, increasing chronic diseases and with fewer working-age people. The pressure is mounting on our healthcare services, our collective well-being, and our economic future.
To build strong and growing economies, we need populations that are healthy and productive. But that won’t happen without action. We need to work together to invest in health systems that are ready for the innovations of today and tomorrow.
Tackling disease and boosting global productivity demands a bold shift: healthcare innovation must be seen as an investment, not a cost.
of life expectancy gains came from pharma innovation from 1990-2015.
(Health Affairs, PhRMA)
of global deaths are from non-communicable diseases.
(2021 GBD Study)
burden by 2032 from MS, HER2+ cancer, and eye diseases – if we don’t act.
(WiFOR)
could generate $2 to $4 in economic benefits.
(McKinsey, Prioritizing Health: A Prescription for Prosperity, 2020)
of EU medicines were available to patients between 2020–2023.
(EFPIA W.A.I.T. Survey 2024)
GDP gain from Roche’s HER2+ medicines (2017–2023).
(WifOR)
GDP gain from our MS medicine.
(WifOR)
Only together can government and industry realise the value of innovation.